2018
DOI: 10.1080/10715762.2018.1516285
|View full text |Cite
|
Sign up to set email alerts
|

The role of decorin in cardiovascular diseases: more than just a decoration

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
16
0

Year Published

2019
2019
2025
2025

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 26 publications
(16 citation statements)
references
References 88 publications
0
16
0
Order By: Relevance
“…For example, DCN interacts with TGF-β, a major activator of fibrinogenesis, to suppress its response. The reduced TGF-β reception can further mitigate inflammation, fibrosis and tissue hypoxia in the context of metabolic disorders such as obesity and non-alcoholic steatohepatitis (NASH) (145).…”
Section: Decorin -Friend or A Foe In Inflammatory Diseases?mentioning
confidence: 99%
“…For example, DCN interacts with TGF-β, a major activator of fibrinogenesis, to suppress its response. The reduced TGF-β reception can further mitigate inflammation, fibrosis and tissue hypoxia in the context of metabolic disorders such as obesity and non-alcoholic steatohepatitis (NASH) (145).…”
Section: Decorin -Friend or A Foe In Inflammatory Diseases?mentioning
confidence: 99%
“…Moreover, the collagen binding protein dcn and Aspn both were increased. dcn is a proteoglycan constituent of the EcM reported to possess powerful anti-inflammation properties in cardiovascular diseases (69). These results suggested that a possible degradation of the collagen component in EcM of the spinal cord and the collagen metabolism may be involved in the regulation in the spinal cord in response to myocardial IR injury in rats.…”
Section: Discussionmentioning
confidence: 85%
“…Note also that decreased autophagy is involved in the pathogenesis of inflammaging, fibrotic diseases and tumors. Studies have shown a reduction of decorin in different fibrotic organs, as in cardiac fibrosis following myocardial infarction and in acute exacerbation-idiopathic pulmonary fibrosis (IPF) (70)(71)(72). Animal experiments in decorin-null mice with myocardial infarction (70) or in hamster and mice models of lung fibrosis (73-75) showed both decorin requirement for proper fibrotic evolution of tissue injury and the potential therapeutic antifibrotic effect of decorin administration.…”
Section: Granzyme B: Epithelial-to-mesenchymal Transition and Fibrosimentioning
confidence: 99%